MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer
Published on 15 April 2026
Dr Adrian Sacher speaks to ecancer about the updated results from the KANDLELIT-001 study evaluating MK-1084, a next-generation KRAS G12C inhibitor, alone and in combination with pembrolizumab in patients with KRAS G12C mutated non-small cell lung cancer.
The combination of MK-1084 with pembrolizumab demonstrated very high clinical activity in treatment-naïve patients, particularly in those with high PD-L1 expression, with durable responses and prolonged progression-free survival observed.
The safety profile was generally manageable, with low rates of severe liver enzyme elevations and a small number of treatment-related serious adverse events.
These findings support continued development of MK-1084 in combination with immunotherapy and underpin the ongoing phase III KANDLELIT-004 trial in the first-line setting.